2) SARS-CoV-2, the infectious agent for COVID-19, has shown mutations in the viral spike protein (S protein) that binds the human angiotensin I-converting enzyme (ACE2) protein. The RBD (ACE2 receptor binding domain) domain of the viral spike protein mutations for SARS-CoV-2 are shown below. (1 point) CRF7ORF A ORFTA ORFMOORNORF0 5' UTR C 3' UTR gene map S protein NTD RBD S2 e CT spike protein Prototype RBD Alpha RBD KA17N Beta R8D mutations in the RBD of the spike protein CATTT Gamma Delta 03005375373057K GD/1/2019 RBD 2a) Pick any two mutations that occur as the prototype mutates to the Omicron variant. Draw out the "before and after" side chain structures and describe how the chemistry of that side chain changes. 2b) The mRNA vaccines encourage human antibody expression against the viral RBD sequence. In general terms, explain how mutations in the RBD residues of the viral spike protein could reduce the effectiveness of mRNA-induced antibody therapeutic approaches.